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Abstract 
Background and aims. High drug related mortality amongst former prisoners in 
the 4 weeks following release is an internationally recognised problem. 
Naltrexone injections at release could diminish this by blockading opioid receptors, 
but naltrexone is not licenced for injection for treating opiate misuse in the United 
Kingdom and some other countries. This study examined the likelihood of 
accepting a naltrexone injection at release, and the relationship of this likelihood 
to other relevant variables.   
Method. Sixty-one male prisoners with a history of heroin use, who were 
approaching release from two prisons in the north-west of England, provided 
likelihood ratings for accepting a naltrexone injection if it were to have been 
available.  Additional data was gathered regarding demographic and drug use 
histories, and also from psychometric instruments relevant to drug misuse and 
treatment preparedness.  
Results. Maximum likelihood ratings for accepting a naltrexone injection were 
recorded by 55.7% of the sample with only 9.8% indicating no likelihood of 
accepting an injection. Likelihood ratings were positively related to serving a 
current sentence for an acquisitive offence compared to drug related or violence 
offences, and negatively related to peak methadone dosages during the current 
sentence.  
Conclusions. Although naltrexone injections were not available to participants in 
this study, the findings suggest that the potential uptake for this intervention is 
sufficient to warrant a clinical trial with this population of British prisoners, with a 
view to potential changes to its current licencing status. However, the importance 
of individual patient readiness for such an abstinence orientated intervention is 
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emphasised by the negative correlation between the likelihood ratings and recent 
methadone doses.  
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1.0 Introduction 
An elevated mortality rate for recently released prisoners with a history of opiate 
misuse, compared to the general population, has been highlighted by the World 
Health Organisation (2014). Evidence from several countries supports this 
observation, with causes of death related to opiate misuse being associated with 
elevated mortality in the first month following prison release (Binswanger et al, 
2007, 2012; Farrell & Marsden, 2005, 2008; Huang et al., 2011; Kariminia et al., 
2007; Singleton, Pendry, Taylor, Farrell, & Marsden, 2003), and particularly within 
the first 2 weeks since release (Merrall et al., 2010). In one study, newly released 
prisoners were reported to be approximately 40 times more likely to die in the 
week following release compared to the general population, with drug related 
causes being reported in approximately 90% of these deaths (Singleton et al., 
2003). A combination of the diminution of opiate tolerance whilst incarcerated, 
and a hedonistic intention to enjoy newly re-acquired freedom, appears to be 
associated with this high prevalence of premature deaths (e.g. Binswanger et al, 
2007; Merrall et al., 2010).  
 
The misuse of drugs is acknowledged as a serious problem in the British criminal 
justice system, which was the context of the present study. In their most recent 
report to address this issue, the House of Commons Home Affairs Committee 
noted that 70% of offenders reported having misused drugs prior to prison 
admission, 51% of offenders were deemed to have drug dependency problems, 
and that 35% of offenders had engaged in injecting behaviour (House of 
Commons, 2012). Furthermore, one survey of British prisoners reported that 19% 
of those who declared that they had used heroin indicated that their first use of 
the drug occurred in prison (Prison Reform Trust, 2012). In response to this 
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situation, detailed clinical guidelines exist for the treatment of substance abuse 
problems in the prison population which acknowledge the importance of both 
maintenance and detoxification strategies in treatment, and which also address 
the need for careful management of the transition back from prison into the 
community (Clinical Guidelines on Drug Misuse and Dependence Update 2017 
Independent Expert Working Group, 2017; NICE, 2007). These guidelines 
emphasise the importance of using opiate substitution treatment (OST) to 
maintain the stability of patients in prison, and that any change in treatment 
strategy to one of detoxification needs to be a matter of clinical judgement 
regarding the patient‟s readiness for this change, in the context of their 
willingness and ability to pursue such a strategy. The guidelines oppose an 
enforced removal of OST and the consequent imposition of opiate withdrawal on 
patients in prison, in line with evidence for the potential benefits to patients of 
continuing the availability of OST in prison (e.g. Rich et al., 2015). Whilst the 
United Kingdom Ministry of Justice acknowledges the role of OST in treating 
opiate dependence in prisons, it also advises that wherever possible, drug 
dependent prisoners be encouraged to pursue a recovery strategy in the form of 
drug abstinence (House of Commons, 2012). In considering the question of 
treatment for opiate misuse amongst prisoners more broadly, it is important to 
remember that the availability of OST will vary across national jurisdictions with, 
for example, limited availability in the United States (Maradiaga, Nahvi, 
Cunningham, Sanchez & Fox, 2016; Mitchell et al., 2009).  
 
One intervention for minimising the risk of a post-release opiate overdose is the 
provision of the opiate antagonist naloxone and the equipment to inject it, so as to 
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counteract the overdose (Bird & Hutchinson, 2003; European Monitoring Centre 
for Drugs and Drug Addiction, 2018; Parmar, Strang, Choo, Meade, & Bird, 2016; 
Strang, 2015). However, this strategy does not diminish the likelihood of an 
overdose initially occurring, and relies upon either the user being sufficiently 
capable of self-administering the injection, or another person being present who 
is capable and willing to administer it. An alternative intervention is the 
administration of the opiate antagonist naltrexone to blockade µ-opiate receptors 
against exogenous opiates such as heroin, and consequently diminish the 
likelihood of positive reinforcement arising from their administration (Adi et al., 
2007; Martin, Jasinski & Mansky, 1973; Schuh, Walsh & Stitzer, 1999). Oral 
administration of naltrexone can provide a dose dependent blockade of µ-opiate 
receptors for between 3 and 5 days, but there is evidence to indicate limited 
effectiveness for relapse prevention (Adi et al., 2007; Coviello, Cornish, Lynch, 
Alterman, & O‟Brien, 2010; Minozzi et al., 2011), with high treatment drop-out 
rates being common. An alternative longer acting administration method for 
naltrexone is by implantation, but the effectiveness and acceptability to patients of 
this intervention compared to conventional treatments have not been clearly 
established (Larney et al., 2014; Lobmaier, KunØe, Gossop, Katevoll, & Waal, 
2010).  
 
Slow release injectable naltrexone formulations offer an effective opiate receptor 
blockade for approximately 4 weeks, which has been shown to contribute to 
relapse prevention (Comer et al., 2002, 2006; Krupitsky & Blokhina, 2010; 
Krupitsky et al., 2011; Lobmaier et al., 2011; Sullivan et al., 2013; Wang et al., 
2014). Consequently, a naltrexone injection at prison release may potentially 
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contribute to curbing post release elevated mortality. Contraindications for the use 
of naltrexone include impairments to both kidney and liver functioning (British 
National Formulary, 2017; Accord Healthcare, 2018). Trials of injectable 
naltrexone with newly released prisoners in the United States show it to be 
acceptable to some prisoners (Friedman, Wilson, Hoskinson, Poshkus & Clarke, 
2018; Gordon et al., 2015; Lee et al., 2015; Vagenas et al, 2014) and effective in 
curbing relapse to opiate use. In one study, a second injection 4 weeks after 
release was shown to be effective in curbing relapse at an 8 week follow-up (Lee 
et al., 2015) in those participants remaining in the trial. Naltrexone is not currently 
licensed for injectable administration for treating opiate misuse in the United 
Kingdom and some other countries such as Holland, with no evidence therefore 
being available concerning its likely uptake by prisoners within these populations 
if it were to be available. However, Dutch patients in community based 
methadone maintenance (MMT) or heroin assisted treatment (HAT) who wished 
to become abstinent have expressed intended acceptance of this intervention 
(Zaaijer, Goudriaan, Koeter, Booij & van den Brink, 2016). 
 
Whilst clinical trials have shown that naltrexone injections were acceptable to 
some prisoners at their time of release, the offer of this treatment was not 
universally accepted. For example, Gordon et al. (2015) reported that 45 potential 
participants declined to participate in their trial, compared to the 97 who did, 
constituting an approximate refusal rate of 31.7%. Lee et al (2015) reported the 
completion of consent procedures with 48 out of 142 potentially eligible 
participants (i.e. 33.8%), but procedural difficulties with screening make it difficult 
to identify a clearly defined refusal rate for this trial. Two other trials only report 
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details of participants who completed the consent procedures (Friedman et al., 
2018; Vagenas et al (2014). The demonstrated effectiveness of the µ-opiate 
receptor blockade following a naltrexone injection (Sullivan et al., 2013; Wang et 
al., 2014) means that, at a subjective level, abstinence from the desired effects of 
opiate misuse is effectively being enforced for a 4 week period, and this may 
pose serious challenges to some potential participants which need to be 
understood at this early stage in the deployment of this intervention. The 
importance of the willing participation of prisoners in an abstinence orientated 
treatment makes this an important research question (Clinical Guidelines on Drug 
Misuse and Dependence Update 2017 Independent Expert Working Group, 2017). 
 
Studies with prisoners approaching release have not so far examined the 
variables associated with the decision to accept injections of naltrexone or not. 
The present study attempted to examine some potentially relevant variables in a 
sample of British prisoners with a history of opiate dependence who were close to 
release into the community. It should be noted that this treatment option was not 
available to them at the time of data collection due to the licencing regulations for 
naltrexone in the United Kingdom. However, the research team considered that 
gathering such data at this time would not only demonstrate a willingness within 
this population to accept the treatment or not, but would also facilitate the delivery 
of the treatment in a timely manner if the licencing situation changed, due to the 
awareness available to treatment providers regarding variables which might be 
associated with the decision of prisoners to accept it or not.   
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The choice of instruments to be administered was guided by issues in treatment 
arising in the existing literature for other interventions and other treatment 
contexts. For example, motivation for treatment and confidence for being able to 
maintain abstinence constitute important elements of a drug dependent patient‟s 
psychological preparedness for treatment (Hampton et al., 2011; Murphy & 
Bentall, 1992; Murphy et al., 2003). Related to motivation and confidence are 
likely to be previous experiences of the challenges of maintaining abstinence 
such as the influence of heroin using associates (Liu et al., 2013; Mullen & 
Hammersley, 2006), coping with craving (Evren et al., 2014; Tasić, Valkanou, 
Đukanović, Banković, & Janjić, 2017), and coping with problems of mood 
(Hammerbacher & Lyvers, 2006; Min et al., 2011). Release into the community is 
also likely to mean a return to the social context where the prisoner will have 
been engaged in crime, with this engagement also having been a feature of their 
social networks, and which may have preceded the misuse of drugs (Allen, 2005; 
Bennett & Holloway, 2006; Kaye, Darke, & Finlay-Jones, 1998). Whilst 
engagement in, and convictions for, acquisitive crime to obtain financial support 
for heroin use, including the trafficking of drugs, has been well reported in the 
literature (Gossop, Trakada, Stewart & Witton, 2005; Stewart, Gossop, Marsden 
& Rolfe, 2000), the corresponding evidence for violent crime by heroin users has 
shown it to be present at a comparatively lower level (Butken et al., 2011; 
Håkansson & Berglund, 2012, Vorma et al, 2013). In short, the relationship 
between crime and drug misuse is complex, and elements of this relationship 
may potentially influence decisions to accept a naltrexone injection or not. Other 
life domains which may influence engagement with treatment include concern for 
one‟s health and/or family relationships (Murphy et al., 2003; Tseng, Hemenwa, & 
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Kawachi, & Subramanian, 2010; Weiss et al., 2014), and concomitant problems 
with alcohol and illegal drugs other than heroin (Fernández-Calderón, Fernández, 
Ruiz-Curado, Verdejio-García, & Lozano, 2015; Reissner et al., 2012).  
 
In summary, the objective of this study was to obtain ratings of the likelihood of 
accepting a naltrexone injection at the time of prison release, if one were to have 
been available, and to examine the relationship of these ratings to variables 
representing aspects of drug dependence, criminal behaviour, and psychological 
preparedness to change substance using behaviours.  
 
2.0 Method 
        2.1 Design and treatment context 
This was an interview based study conducted in HMPs Liverpool and Kennet in 
the north-west of England where the treatment of prisoners with opiate 
dependence problems followed the national treatment guidelines for the United 
Kingdom. These guidelines encompass both maintenance and detoxification 
strategies, with all prisoners being screened for opiate misuse at admission. 
Those who prove positive for opiate misuse are offered immediate OST in order 
to stabilise patients their condition. In rare cases where OST is refused at 
admission, prison medical staff follow-up the initial contact in the days following 
admission to encourage acceptance of this treatment. The normal practice is to 
maintain a stabilised state for at least 3 months before encouraging these 
patients to attempt detoxification if clinical judgement deemed this to be 
appropriate, with a drug free state being the long term goal. Where patients were 
still in receipt of methadone at the time of their prison discharge, possibly due to 
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serving only a short sentence or because attempted abstinence was 
contraindicated, they are referred to community drug treatment agencies and 
narcotics anonymous for continuing care. Within this context, all participants in 
this study would have been stabilised on methadone as part of their current 
treatment plan before moving to a strategy of detoxification and abstinence. 
Where patients are abstinent at prison release, they are actively encouraged to 
seek support from community based agencies in order to maintain abstinence in 
the face of pressures to relapse to opiate misuse. 
 
For the purposes of this study the intention was to recruit participants for whom 
the current strategic objective of treatment was abstinence upon release without 
OST, as determined by prevailing clinical procedures. Consequently, there was 
an inclusion criterion that methadone prescribing had either already been ceased 
for these prisoners, or that its cessation was planned to have been completed by 
the time of their release. This criterion was used to identify the potential 
participants to be targeted for recruitment to this study because they would be the 
potential candidates to receive naltrexone by injection, if it were to have been 
available, in order to provide additional support for the maintenance of abstinence 
after release, and therefore the consequent diminution of overdose risks.  
However, with no drug being administered in the present study, it was not 
possible to reproduce the conditions which would prevail for a clinical trial or 
treatment programme of injectable naltrexone, such as liver function tests and 
additional urine screening. Furthermore, in the absence of the funding 
arrangements which would support a clinical trial, the access of the research 
team to the prisoners was contingent upon the minimisation of additional work for 
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the prison medical team. Where their time permitted, the medical staff in both 
prisons identified patients who satisfied the inclusion criteria concerning the 
cessation of methadone, described above, and ascertained their willingness or 
otherwise to meet the researcher for an interview. However, they were not in a 
position to keep additional records of such approaches.  
 
2.2 Participants 
Sixty-one participants (all male) agreed to meet the member of the research team 
conducting the interviews (MW). In addition to the inclusion criterion described 
above concerning OST, an additional exclusion criterion had been that potential 
participants would not reasonably be expected to pose a threat to the safety of a 
female researcher. All the potential participants who agreed to meet the 
researcher completed the full research interview. Table 1 summarises 
participants‟ background measures with regard to age, opiate misuse histories, 
and sentencing histories. 
Insert Table 1 about here 
 
     2.3  Materials and Measures 
Participant Information Sheet. This explained the ability of one naltrexone 
injection to prevent psychoactive effects from heroin use for approximately 4 
weeks. It was emphasised that no naltrexone injection would be available in this 
study, with the focus being upon how participants thought they would respond if 
an injection was available. However, this sheet did not explain the medical 
contraindications for this intervention because it was not possible to create the 
conditions under which such information is given within clinical trials. These 
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include the use of a test dose of oral naltrexone to examine potential adverse 
effects prior to commencing the injections (e.g. Gordon et al., 2015). The 
participant information sheet also explained the procedures for maintaining 
confidentiality and withdrawal from the study. The voluntary nature of participation 
was emphasised, along with the absence of both financial incentives for 
participation and penalties for not participating. Participants were informed they 
could proceed with the full interview now, decide not to participate, or wait for up 
to 2 days to decide to participate or not. This information sheet had a Flesch-
Kincaid score of 9.7, compatible with a reading age of 13 to 14 years.  
 
Background Information. Data concerning heroin consumption immediately prior 
to the current sentence were obtained using a brief questionnaire. However, 
participants‟ ages, longer-term opiate misuse histories and treatment details, 
were obtained from patient medical records held within the prison treatment 
facility, which were part of the national health service record system, rather than 
the criminal justice record system. However, a detailed history of substance 
misuse consumption was not sought because of the potential level of threat which 
participants might have experienced in providing such data, given their position 
within prison with the opportunity of discharge into the community approaching.  
 
Naltrexone Treatment Questionnaire (NTQ). Participants rated the likelihood of 
being willing to receive an injection of naltrexone prior to prison release on a 
visual analogue scale. The left pole was labelled „I would not accept this 
treatment‟ and the right pole was labelled „I would certainly accept this treatment‟. 
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The measures obtained represented the distance of responses from the left pole 
in millimetres (maximum 135 mm).  
 
The Leeds Dependence Questionnaire (LDQ: Kelly, Magill, Slaymaker, & Kahler, 
2010; Raistrick et al.,1994). Participants rated their substance use related 
thoughts and behaviours on 10 items concerning preparedness for treatment 
using a four point scale of „Never‟, „Sometimes‟, „Often‟, and „Nearly Always‟. This 
instrument measures various elements of dependence upon a drug, such as 
continual thinking about its use, a perceived need to use it which is too strong to 
control, and perceived difficulty in daily functioning without its consumption.  
 
Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES 8A 
Personal Drinking Questionnaire, and 8D Personal Drug Use Questionnaire: 
Miller & Tonigan,1996). These two instruments derived from the transtheoretical 
model of change (Prochaska & DiClemente, 1986) addressed aspects of 
psychological preparedness to change consumption behaviours for alcohol and 
other drug use, respectively, including concerns over the harm these behaviours 
may be causing to self and others which may be motivational elements 
underpinning treatment choices. Each instrument contained 19 items, yielding 
scores on three scales (i.e. six scales in total) representing, respectively, 
recognition of an alcohol/drug problem, ambivalence regarding alcohol/drug use, 
and taking steps regarding alcohol/drug use. The response format for each item 
was a five point scale of „No! strongly Disagree‟, „No: Disagree‟, „?: Undecided or 
Unsure‟, „Yes: Agree‟, and „Yes! Strongly Agree‟.  
 
Running head: Naltrexone injections at prison release 
 
15 
 
Drug-Taking Confidence Questionnaire (DTCQ-8: Sklar & Turner, 1999). 
Respondents imagined themselves reacting to a list of eight hypothetical 
situations of temptation to use heroin. Under the overall question „I would be able 
to resist the urge to use heroin‟, each situation was rated on a six point scale with 
„0‟ labelled „Not at all confident‟, and „100‟ labelled „Very confident‟. The 
intermediate points represented percentage estimates of confidence to resist 
using heroin labelled as „20‟, „40‟, „60‟, and „80‟, respectively. The hypothetical 
situations presented include social influences from heroin using associates.  
      
2.4  Procedure 
 
Interviews were conducted in the prisons' clinical facilities, with only the 
interviewee and interviewer (MW) present, and were divided into Part 1 and Part 
2. In Part 1, participants read the Participant Information Sheet with the 
interviewer providing brief oral summaries to ensure correct understanding. Part 2 
comprised administration of the measures listed above, in the order listed. Ethical 
approval for this study was obtained from an appropriate NHS Research Ethics 
Service Committee with a remit for prison based research, NHS Trusts providing 
clinical services in the participating prisons, the National Offender Management 
Service, and fro, the Edge Hill University (EHU) Faculty of Health and Social Care 
Research Ethics Committee.  
 
     2.5  Analytic Strategy 
Data were stored and analysed using SPSS ™. An anonymised data file is 
available as supplementary information through the publisher‟s website. Data 
from the LDQ, SOCRATES, and the DTCQ-8 were labelled as treatment 
preparedness scores. Descriptive statistics for all variables included skewness 
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and kurtosis measures of approximation to a normal distribution, and the 
consequent appropriateness of parametric analyses (Tabachnick &  Fidell, 2014). 
Bivariate correlations measured the relationship of naltrexone injection 
acceptance likelihood (NIAL) ratings to demographic and treatment preparedness 
variables.  The type of offence for which participants were currently incarcerated 
constituted an independent variable for parametric ANOVAs and post hoc 
pairwise comparisons. Where nonparametric Kruskal-Wallis tests were necessary 
instead of ANOVAs, post hoc comparisons utilised Mann-Whitney U tests. In both 
cases, post hoc comparisons were evaluated as two-tailed against Bonferroni 
adjusted alpha levels. Results from bivariate correlations and ANOVAs informed 
the development of a predictive model for multiple linear regression analysis 
utilising NIAL ratings as the dependent variable. Squared semi-partial correlation 
coefficients (sr2) for each independent variable made it possible to examine their 
relationship individually with the variability in the dependent variable (Tabachnick 
&  Fidell, 2014).  
 
Limitations to the NIAL ratings as a dependent variable are acknowledged as they 
essentially possess an ordinal level of measurement rather than a more robust 
interval level. One means of addressing this limitation would be to dichotomise 
the NIAL ratings to serve as a dependent variable in a logistic regression analysis. 
However, whilst acknowledging that the dichotomisation of a continuous variable 
may sometimes be useful, such a step can also produce a spurious result with 
regard to the creation of an arbitrary dichotomy where the variability of scores is 
ignored so that participants close to, but on opposite sides of the cut-off point, are 
assumed to be different on the variable in question to the same extent as 
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participants with either the lowest or the highest scores, respectively (Altman & 
Royston, 2006; Iacobucci, Posavac, Kardes, Schneider & Popovitch, 2015). 
Consequently, the decision to include such a logistic regression analysis or not 
was made dependent upon the obtained distribution of NIAL scores.  
 
3.0 Results 
3.1   Background variables and treatment preparedness measures 
Details of participants‟ ages, opiate misuse histories, and sentencing histories are 
shown in Table 1, whilst Table 2 shows the four categories of offence identified 
for which participants were currently incarcerated, with scores for the treatment 
preparedness measures broken down by these four groups. The miscellaneous 
offences group was omitted from inter-groups analyses because of its small size. 
The Bonferroni adjusted alpha level was therefore ά = .017. 
Insert Table 2 about here 
Table 2 shows no significant effects for the LDQ, SOCRATES drug problem 
scales, or the DTCQ-8.  Significant inter-group effects were found on each of the 
SOCRATES alcohol problem scales. The violent offences group scored 
significantly higher than the drug misuse offences group for „recognition of an 
alcohol problem‟ (P = .009, two tailed), and for „ambivalence regarding an alcohol 
problem‟ (P = .011, two tailed). No other comparisons were significant for these 
scales. For the „taking steps regarding an alcohol problem‟ scale, the violent 
offences group scored higher than both the drug misuse offences (P = .003, two-
tailed), and the acquisitive offences group (P = .011, two tailed). The remaining 
pairwise comparison was nonsignificant.  
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3.2   Naltrexone injection acceptance likelihood (NIAL) ratings 
The mean NIAL visual analogue scale rating was 76.6 mm (SD = 32.5 mm), 
ranging from 0 mm to the maximum rating of 135 mm. The median and mode 
scores were both 135 mm. Only 6 participants (9.8%) recorded NIAL ratings of 0 
mm., with the ratings for a further 13 participants (21.3%) falling below the equal 
likelihood rating of 67.5 mm. In total therefore, 19 participants (31.1%) recorded 
NIAL ratings below the point of equal likelihood. Forty-two participants (68.9%) 
recorded NIAL ratings beyond the equal likelihood rating of 67.5 mm, with 8 
participants (13.2%) recording ratings between the equal likelihood point and 90.0 
mm. Beyond this point on the scale, the remaining 34 (55.7%) participants 
recorded maximum NIAL ratings of 135 mm. Table 2 reports a significant main 
effect for NIAL ratings across the three offence groups included in the 
nonparametric ANOVA. The only significant post hoc comparison showed that the 
acquisitive offences group had significantly higher ratings than the drug misuse 
offences group (U = 152.5, p = .013, two tailed). From the other variables detailed 
in both Tables 1 and 2, only the highest daily methadone dosage during the 
current sentence (rs (61) = -.256, p = .046, two tailed) was correlated with NIAL 
ratings.  
 
The linear regression model utilised a binary independent variable of „acquisitive 
offence or not‟ for Model 1, as this group had the highest NIAL ratings of the three 
main offences group. All 61 participants were included in this binary coding. Using 
hierarchical variable entry, „highest daily methadone dosage during the current 
sentence‟ was added as an independent variable for Model 2 due to its significant 
correlation with the dependent variable. Both models significantly predicted NIAL 
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ratings. For Model 1, R2 = .089 (F (1, 59) = 5.794, P = .019). For Model 2 there 
was a small increase in the proportion of variance in NIAL ratings explained, with 
R2 = .110 (F (2, 58) = 3.583, P = .034), but this increase was nonsignificant (F 
change (1, 58) = 1.339, ns.). Table 3 shows that „Acquisitive crime or not‟ was a 
significant predictor of NIAL ratings in both models, with the positive B coefficient 
indicating that membership of this offender group was associated with higher 
ratings. Obtained z-scores for skewness and kurtosis for unstandardized 
residuals for both models showed no significant deviation from a normal 
distribution. Residual plots showed no indication of curvilinearity or 
heteroscadesticity.  Post hoc statistical power calculations for f2 = 0.35 were 
0.995 for Model 1 and 0.986 for Model 2 (Faul & Eerdfelder, 1992).  
Insert Table 3 about here 
The distribution of NIAL ratings showed a clear dichotomy between participants 
with maximum ratings of 135 mm (n = 34), and the remainder of the sample (n = 
27) for whom the highest rating was 90 mm. It was considered that this dichotomy  
constituted a clear and potentially meaningful outcome at a psychological level, 
so that we proceeded with a logistic regression analysis utilising maximum NIAL 
ratings or not as a dichotomous dependent variable. This analysis utilised Models 
1 and 2 as described above (see Table 4). The correct prediction percentage for 
Block 0 (i.e. random prediction) was 55.7%. There was a nonsignificant rise to 
60.7% correct prediction for Model 1 (Model χ2 [1 (N = 61)] =2.884, P = .089), 
whilst Model 2 raised the correct prediction percentage to 62.3% which was 
significantly higher than for Block 0 (Model χ2 [2 (N = 61)] = 5.993, P = .050). The 
positive B coefficients for „acquisitive crime or not‟ show that membership of this 
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group was associated with maximum NIAL ratings, although the Wald chi-square 
results were nonsignificant regarding prediction of the dependent variable.  
Insert Table 4 about here 
 
4.0   Discussion 
Clinical trials conducted in the United States have shown that some prisoners 
with a history of opiate misuse who are approaching release into the community 
are willing to accept a naltrexone injection, but that acceptance of this treatment 
is not universal (Gordon et al., 2015; Lee et al., 2015). The present findings 
indicate a strongly positive response from a comparable sample of British 
prisoners regarding their willingness to receive a naltrexone injection if one were 
to have been available at their time of release.  More than half of the sample 
recorded a maximum likelihood rating that they would accept such an injection, 
despite being aware that it would prevent them from experiencing a „high‟ 
resulting from the use of heroin for up to 4 weeks thereafter. This finding suggests 
that the likely acceptance of this intervention exists in licencing jurisdictions where 
it is not currently permitted, outside the United States. However, as this 
intervention was not available to the present participants, the implications of this 
finding are necessarily limited. In particular, there is a strong need for caution 
around the assumption that actual behaviour would correspond to intentions 
stated at a time when there was no possibility of being required to follow through 
with a behavioural commitment to pursue an intervention which would effectively 
prevent the sought after effects of opiate consumption.  
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One further limitation to the current findings is that despite being statistically 
significant, only 11.0% of variability in NIAL ratings was explained by Model 2 in 
the linear regression. It is possible that the high proportion of maximum NIAL 
ratings created a ceiling effect which consequently limited the possibility of 
variability being shared between the treatment preparedness and other measures 
as independent variables, and the NIAL ratings as the dependent variable in this 
analysis. Despite satisfactory post hoc statistical power for the multiple linear 
regression, the present study would have benefited from having a larger sample 
size to facilitate the exploration of the bivariate relationships between the 
treatment preparedness and other variables, and the willingness to accept a 
naltrexone injection. The size of the present data set renders it unclear as to 
whether the reported paucity of significant bivariate correlations in these results is 
due to a ceiling effect concerning the NIAL ratings, or a need for greater statistical 
power. The significant negative correlation between the highest methadone 
dosage received during the current sentence and the NIAL ratings raises 
questions concerning participants‟ perceptions‟ of their readiness to change from 
OST to an abstinence orientated treatment strategy. Indeed, the zero NIAL 
ratings by given by some participants could be indicative of a reluctance to 
commit themselves entirely to treatment goal of abstinence.  Whilst some patients 
receiving OST may feel ready to change to an abstinence orientated treatment 
strategy (see also Zaaijer et al., 2016), the continuation of OST has been 
demonstrated to have potential health benefits for prisoners with a history of 
opiate misuse (e.g. Rich et al., 2015), and the importance of clinical judgement 
regarding the readiness of such prisoners to change to an abstinence treatment 
strategy, and the prisoners own active engagement with such a strategy, must be 
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remembered (Clinical Guidelines on Drug Misuse and Dependence Update 2017 
Independent Expert Working Group, 2017). The provision of information to 
prisoners regarding the possible side effects of naltrexone and appropriate clinical 
screening procedures would also be required as part of their preparation for the 
administration of this treatment (British National Formulary, 2017; Accord 
Healthcare, 2018). 
 
Serving a current sentence for an acquisitive crime compared to a drug misuse, 
violent, or miscellaneous offence, was the strongest predictor of high NIAL ratings. 
With acquisitive crimes often committed to support heroin use (Gossop et al., 
2005; Stewart et al., 2000), this result may indicate greater willingness in this 
offender group to accept an intervention which will remove any reason to find 
money to acquire heroin, compared to the other offender groups. It should be 
noted that higher post release mortality has previously been reported for this 
offender group than for other types of offences (Farrell & Marsden, 2005). With 
regard to the violent offences group, it is noteworthy that they scored significantly 
more highly than the drug misuse offences group on all three SOCRATES alcohol 
scales, and more highly than the acquisitive offences group on the „taking steps‟ 
alcohol scale. Violent offences have been reported to be uncharacteristic of 
heroin users except in situations of desperation for money to obtain the drug 
(Butken et al., 2011; Håkansson & Berglund, 2012, Vorma et al, 2013), and 
possibly more characteristic of cocaine and alcohol use (Stewart et al., 2000). It is 
possible, therefore, that prisoners with opiate misuse problems who are serving 
sentences for violent offences may be more likely than other prisoners with opiate 
misuse problems to have concurrent problems with alcohol, and possibly other 
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substances, and to be relatively less willing to accept a naltrexone injection than 
their counterparts who are serving sentences for acquisitive crimes. However, 
although the concomitant use of alcohol and other drugs with heroin is noted in 
the literature (e.g. Fernández-Calderón et al., 2015; Reissner et al 2012), this 
point cannot be pursued further with the current data set due to the lack of data 
concerning the consumption of other substances arising from the context of data 
collection for this study: 
 
Whilst issues of sample size and the absence of naltrexone injections for the 
participants in this study place some limitations on the application of the present 
findings, there are nevertheless some potentially important implications arising 
from this study with regard to the deployment of this intervention. In particular, it 
appears likely that where opiate abstinence at prison release was deemed to be 
an appropriate option, there would be a worthwhile number of British prisoners 
who have received treatment for heroin use during their current sentence willing 
to come forward, in order to justify either a trial of this intervention to be 
conducted within the United Kingdom, or for the current licencing situation for 
naltrexone to change in order to permit the availability of this intervention. In this 
sense, the present findings constitute a „proof of concept‟ for this intervention with 
this population of prisoners for whom it is currently unavailable. Rather than being 
solely a British situation, it should be remembered that the post release elevation 
of mortality for this population of prisoners has been noted in many countries 
(World Health Organisation, 2014), so that the existence or not of a willingness to 
accept this intervention, and the identification of issues associated with its 
acceptance or refusal, is a matter of interest internationally with regard to 
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changes in treatment provision and/or regulation in jurisdictions more broadly 
where injectable naltrexone for the treatment of opiate misuse is currently 
unavailable.  
 
Whilst the practice in the prisons participating in this study was to stabilise opiate 
dependent prisoners on OST before consideration of a change of treatment 
strategy towards abstinence, it is noted that within some jurisdictions such as the 
United States, OST has limited availability within prisons, and that the experience 
of enforced opiate withdrawal arising in this context can militate against some 
prisoners being willing to accept OST in the future where it is available 
(Maradiaga et al., 2016; Mitchell et al., 2009). Enforced withdrawal in prison 
would lead to a reduced opiate tolerance upon release, which is one of the 
conditions associated with an increased risk of death from opiate overdose in the 
immediate period following prison release (Binswanger et al, 2007, 2012; Merrall 
et al., 2010). Within the British context where OST is available in prisons, the 
clinical experience available within the present research team indicates that very 
few prisoners refuse this treatment, although we are unaware of any 
comprehensive or systematically gathered data on this point. Whilst noting the 
benefits of OST availability within prisons (Rich et al., 2015), where such 
treatment remains unavailable, there is still a potential role for injectable 
naltrexone to be offered as a support for post-release abstinence.  
 
In conclusion, an effective response to the problems related to opiate misuse 
requires a battery of interventions which can be drawn upon as appropriate.  
Injections of naltrexone provide one clinical means of potentially reducing drug 
Running head: Naltrexone injections at prison release 
 
25 
 
related elevated mortality rates in prisoners in the 4 weeks following their release 
into the community, and its availability as an option to prevent unnecessary 
deaths does not preclude the provision of other interventions such as „take-home‟ 
naloxone supplies (European Monitoring Centre for Drugs and Drug Addiction, 
2018; Strang, 2015). It is recommended that further investigations take place into 
the effectiveness of naltrexone injections as an intervention for the population of 
heroin users facing release from prison, and into the regulatory changes which 
may be necessary for its implementation.  
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Table 1 
Participants‟ age, opioid misuse, and incarceration details for Study 1 
Variable Mean SD Range 
Current age (years) 37.8 6.8 23 to 55 years 
Heroin use onset age (Years) 20.8 6.5 11 to 51 years 
Time elapsing since heroin use onset 
(Years) 
17.0 8.6 1 to 31 years 
Number of overdose episodes 
experienced 
1.6 4.0 0 to 20 episodes 
Highest daily methadone dosage in 
current sentence (mg)  
53.0 33.4 0 to 180 mg 
Length of current sentence (months)1 30.8 23.2 1 to 84 months 
Current sentence served (weeks)2 56.5 98.2 1 to 634 weeks 
Number of previous custodial sentences 15.4 21.3 0 to 99 previous sentences 
1 Excludes 10 prisoners on remand in custody. 2 Includes prisoners on remand. 
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Table 2 
Scores for the treatment preparedness measures and likelihood ratings for 
accepting injectable naltrexone across participant offence groups 
Preparedness 
measure 
Acquisitive 
offence 
Mean (SD) 
n = 30 
Drug misuse 
offence 
Mean (SD) 
n = 17 
Violent 
offence 
Mean (SD) 
n = 10 
Miscellaneous 
offences 
Mean (SD) 
n = 4 
ANOVA1 
(excluding the 
miscellaneous 
offences group) 
Leeds Dependency 
Questionnaire  
(min = 0: max = 30) 
11.40 (7.31) 6.82 (7.10) 7.50 (6.72) 4.25 (3.30) F(2, 54) = 2.626 
ns. 
SOCRATES: 
recognition of an 
alcohol problem 
(min = 5: max = 35) 
16.33 (11.76) 12.77 (9.66) 24.60 (10.63) 11.50 (9.00) F(2, 54) = 3.691 
P = .031, 2p = .120 
SOCRATES: 
ambivalence 
regarding an 
alcohol problem 
(min = 4: max = 20) 
8.90 (6.29) 6.71 (5.28) 12.90 (5.45) 6.50 (5.00) F(2, 54) = 3.507 
P = .037, 2p = .115 
SOCRATES: taking 
steps regarding an 
alcohol problem 
(min = 8: max = 40) 
19.33 (13.50) 15.65 (12.63) 32.00 (13.00) 12.75 (9.50) F(2, 54) = 5.089 
P = .009, 2p = .159 
SOCRATES: 
recognition of a 
drug problem 
(min = 5: max = 35) 
29.10 (8.92) 27.59 (7.34) 30.20 (6.81) 26.75 (9.95) χ2 [2, N = 57] = 
2.536, ns. 
SOCRATES: 
ambivalence 
regarding a drug 
problem 
(min = 4: max = 20) 
15.73 (4.28) 14.88 (2.50) 15.30 (3.23) 14.75 (4.11) χ2 [2, N = 57] = 
2.164, ns. 
SOCRATES: taking 
steps regarding a 
drug problem 
(min = 8: max = 40) 
35.97 (7.01) 36.06 (4.70) 37.70 (3.68) 34.75 (10.50) χ2 [2, N = 57] = 
1.049, ns. 
DTCQ-8 (min = 0: 
max = 100) 
62.08 (25.23) 60.88 (28.78) 76.51 (22.99) 63.13 (40.28) F (2, 54) = 1.359, 
ns. 
Highest methadone 
dosage for current 
sentence (mls) 
49.83 (36.35) 61.77 (36.18) 47.00 (11.83) 53.75 (39.03) χ2 [2, N = 57] = 
1.484, ns. 
Likelihood of 
accepting injectable 
naltrexone ratings 
(mm: min = 0: max 
= 135) 
110.50 
(38.06) 
75.59 (50.65) 80.50 (59.65) 113.75 (42.50) χ2 [2, N = 56] = 
6.652, P = .036 
1 The choice of parametric or nonparametric ANOVA was based upon the extent of deviation 
   from a normal distribution of scores. Where appropriate the Kruskal-Wallis nonparametric  
   ANOVA was performed. The miscellaneous offences group was omitted due to its small size. 
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Table 3 
 
Hierarchical multiple linear regression results for independent variables within 
modelsa 
a
 Dependent variable: likelihood ratings for accepting injectable naltrexone prior to prison release. 
b 
Squared semi-partial correlation coefficient 
 
 
Independent variables Unstandardised 
B 
t - test sr2 b 
Model One: 
Acquisitive crime or not 
 
(Constant) 
 
28.403 
 
(82.097) 
 
t (59) = 2.407, P = .019 
 
.089 
Model Two: 
Acquisitive crime or not 
 
Highest methadone dose 
during current sentence 
 
(Constant) 
 
27.138 
 
-0.206 
 
 
(93.637) 
 
t (58) = 2.297, P = .025 
 
t (58) = -1.157, ns. 
 
.081 
 
.021 
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Table 4 
Hierarchical logistic regression results for independent variables within modelsa 
 
Independent variables B Wald χ2(1 df) P Exp (B) 
Model One 
 
Acquisitive crime or not 
 
(Constant) 
 
 
 
   .887 
 
(-.194) 
 
 
2.809 
 
 
.094 
 
 
2.429 
Model Two 
 
Acquisitive crime or not 
 
Highest methadone dose 
during current sentence 
 
(Constant) 
 
 
 
 .850 
 
-.015 
 
 
(.630) 
 
 
2.446 
 
2.678 
 
 
.118 
 
.102 
 
 
2.340 
 
.985 
a Dependent variable: Maximum likelihood rating of accepting injectable 
naltrexone at prison release, or not. 
 
 
